News

The trial established the pharmacokinetics of the protein and demonstrated that single dose, intravenous administration of PRX-105 is safe and well tolerated. Protalix plans to perform additional safety

Lixisenatide is a Zealand-invented GLP-1 (glucagon-like-peptide-1) receptor agonist for the treatment of type-2 Diabetes, and uses Zealand’s proprietary SIP (structure inducing probe) peptide modification technology. Previously, in April

The license is extended to register, manufacture and commercialise Tapentadol in additional regions, including selected Asia Pacific, Latin American, African, and New European countries including Turkey and Greece,

Merck Serono’s proprietary oral formulation of cladribine (Cladribine tablets) is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly

Algicell Ag is an antimicrobial silver alginate dressing that delivers 1.4% ionic silver at a slow consistent release rate for broad-spectrum efficacy. Derma Sciences claimed that Algicell Ag

Amy Hu, president and CEO of Niusule, said: “We believe that the animal health products industry in China is promising and will grow rapidly in the next 10

Nautilus claimed that, Cambia, a novel, water-soluble, buffered diclofenac potassium powder, is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Cambia is

The collaboration is to develop and market Durect’s Posidur (Saber-bupivacaine) a long-acting version of the anesthetic bupivacaine currently in Phase III clinical trials. Reportedly, Hospira is expected to

DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects. Depomed claimed that the